Celldex Therapeutics Q3 EPS $(0.81) Misses $(0.68) Estimate, Sales $1.52M Beat $580.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics reported Q3 losses of $(0.81) per share, missing the analyst consensus estimate of $(0.68) by 19.12%. This is a 42.11% decrease from the same period last year. However, the company reported quarterly sales of $1.52 million, beating the analyst consensus estimate of $580.00 thousand by 161.55%, a 272.73% increase from last year.
November 02, 2023 | 8:59 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Celldex Therapeutics' Q3 earnings per share missed estimates, but sales exceeded expectations.
While Celldex Therapeutics missed earnings per share estimates, the company significantly beat sales estimates. This mixed result could lead to neutral short-term price movement as investors weigh the impact of lower earnings against higher sales.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100